The production and immunogenicity of human papillomavirus type 58 virus-like particles produced in Saccharomyces cerevisiae
First Online: 04 November 2012 Received: 29 May 2012 Accepted: 19 June 2012 DOI:
Cite this article as: Kwag, H., Kim, H.J., Chang, D.Y. et al. J Microbiol. (2012) 50: 813. doi:10.1007/s12275-012-2292-1 Abstract
Human papillomavirus (HPV) is the cause of most cases of cervical cancer. HPV type 58 (HPV58) is the second most frequent cause of cervical cancer and high-grade squamous intraepithelial lesions (HSIL) in Asia and South / Central America, respectively. However, there is no vaccine against HPV58, although there are commercially available vaccines against HPV16 and 18. In this study, we produced HPV58 L1 protein from
Saccharomyces cerevisiae, and investigated its immunogenicity. We first determined the optimum period of culture for obtaining HPV58 L1. We found that a considerable portion of the HPV58 L1 resulting from 48 h culture cannot be recovered by purification, while the HPV58 L1 resulting from 144 h culture is recovered efficiently: the yield of HPV58 L1 finally recovered from 144 h culture was 2.3 times higher than that from 48 h culture, although the production level of L1 protein from 144 h culture was lower than that from 48 h culture. These results indicate that the proportion of functional L1 protein from 144 h-cultured cells is significantly higher than that of 48 h-cultured cells. The HPV58 L1 purified from the 144 h culture was correctly assembled into structures similar to naturally occurring HPV virions. Immunization with the HPV58 L1 efficiently elicited anti-HPV58 neutralizing antibodies and antigen-specific CD4+ and CD8+ T cell proliferations, without the need for adjuvant. Our findings provide a convenient method for obtaining substantial amounts of highly immunogenic HPV58 L1 from S. cerevisiae. Keywords human papillomavirus vaccine Saccharomyces cerevisiae virus-like particle immunogenicity
Supplemental material for this article may be found at
. http://www.springer.com/content/120956 Electronic Supplementary Material
Supplementary material is available for this article at
and is accessible for authorized users. 10.1007/s12275-012-2292-1 References Bao, Y.P., Li, N., Smith, J.S., and Qiao, Y.L.
2008. Human papillomavirus type distribution in women from Asia: a meta-analysis.
Int. J. Gynecol. Cancer 18
PubMed CrossRef Bishop, B., Dasgupta, J., Klein, M., Garcea, R.L., Christensen, N.D., Zhao, R., and Chen, X.S.
2007. Crystal structures of four types of human papillomavirus L1 capsid proteins: understanding the specificity of neutralizing monoclonal antibodies.
J. Biol. Chem. 282
PubMed CrossRef Bosch, F.X., Lorincz, A., Munoz, N., Meijer, C.J., and Shah, K.V.
2002. The causal relation between human papillomavirus and cervical cancer.
J. Clin. Pathol. 55
PubMed CrossRef Buck, C.B., Thompson, C.D., Pang, Y.Y., Lowy, D.R., and Schiller, J.T.
2005. Maturation of papillomavirus capsids.
J. Virol. 79
PubMed CrossRef Chan, S.Y., Delius, H., Halpern, A.L., and Bernard, H.U.
1995. Analysis of genomic sequences of 95 papillomavirus types — Uniting typing, phylogeny, and taxonomy.
J. Virol. 69
PubMed Chan, P.K., Li, W.H., Chan, M.Y., Ma, W.L., Cheung, J.L., and Cheng, A.F.
1999. High prevalence of human papillomavirus type 58 in Chinese women with cervical cancer and precancerous lesions.
J. Med. Virol. 59
PubMed CrossRef Clifford, G., Franceschi, S., Diaz, M., Munoz, N., and Villa, L.L.
2006. Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases.
CrossRef Conway, M.J., Alam, S., Ryndock, E.J., Cruz, L., Christensen, N.D., Roden, R.B., and Meyers, C.
2009. Tissue-spanning redox gradient-dependent assembly of native human papillomavirus type 16 virions.
J. Virol. 83
PubMed CrossRef Conway, M.J. and Meyers, C.
2009. Replication and assembly of human papillomaviruses.
J. Dent. Res. 88
PubMed CrossRef Garland, S.M. and Smith, J.S.
2010. Human papillomavirus vaccines: current status and future prospects.
PubMed CrossRef Hara, H., Honda, A., Suzuki, H., Sata, T., and Matsukura, T.
2004. Detection of human papillomavirus type 58 in polydactylous Bowen’s disease on the fingers and toes of a woman-concurrent occurrence of invasive vulval and cervical carcinomas.
PubMed CrossRef Jiang, Z., Tong, G., Cai, B., Xu, Y., and Lou, J.
2011. Purification and immunogenicity study of human papillomavirus 58 virus-like particles expressed in
. Protein Expr. Purif.
PubMed CrossRef Kemp, T.J., Hildesheim, A., Safaeian, M., Dauner, J.G., Pan, Y., Porras, C., Schiller, J.T., Lowy, D.R., Herrero, R., and Pinto, L.A.
2011. HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection.
PubMed CrossRef Kim, S.N., Jeong, H.S., Park, S.N., and Kim, H.-J.
2007. Purification and immunogenicity study of human papillomavirus type 16 L1 protein in
J. Virol. Methods 139
PubMed CrossRef Kim, S.Y., Kim, H.J., and Kim, H.-J.
2011. Simple and convenient chromatography-based methods for purifying the pseudovirus of human papillomavirus type 58.
Protein Expr. Purif. 76
PubMed CrossRef Kim, H.J., Kim, S.Y., Lim, S.J., Kim, J.Y., Lee, S.J., and Kim, H.-J.
2010a. One-step chromatographic purification of human papillomavirus type 16 L1 protein from
Protein Expr. Purif. 70
PubMed CrossRef Kim, H.J., Lee, S.J., and Kim, H.-J.
2010b. Optimizing the secondary structure of human papillomavirus type 16 L1 mRNA enhances L1 protein expression in
J. Biotechnol. 150
PubMed CrossRef Kim, H.J., Lim, S.J., Kim, J.Y., Kim, S.Y., and Kim, H.-J.
2009. A method for removing contaminating protein during purification of human papillomavirus type 18 L1 protein from
Arch. Pharm. Res. 32
PubMed CrossRef Kim, H.J., Lim, S.J., and Kwag, H.L.
2012. The choice of resin-bound ligand affects the structure and immunogenicity of column-purified human papillomavirus type 16 virus-like particles.
PLoS ONE 7
PubMed CrossRef Laemmli, U.K.
1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4.
PubMed CrossRef Madrid-Marina, V., Torres-Poveda, K., Lopez-Toledo, G., and Garcia-Carranca, A.
2009. Advantages and disadvantages of current prophylactic vaccines against HPV.
Arch. Med. Res. 40
PubMed CrossRef Matsukura, T. and Sugase, M.
1990. Molecular cloning of a novel human papillomarvirus (type 58) from an invasive cervical carcinoma.
PubMed CrossRef National Cancer Institute. 2007. Women’s Health Report, Fiscal Years 2005–2006. NCI Women’s Health Report FY2005-2006. Nyari, T., Cseh, I., Woodward, M., Szollosi, J., Bak, M., and Deak, J.
2001. Screening for human papillomavirus infection in asymptomatic women in Hungary.
Hum. Reprod. 16
PubMed CrossRef Nyari, T.A., Kalmar, L., Deak, J., Szollosi, J., Farkas, I., and Kovacs, L.
2004. Prevalence and risk factors of human papilloma virus infection in asymptomatic women in southeastern Hungary.
Eur. J. Obstet. Gynecol. Reprod. Biol. 115
PubMed CrossRef Park, M.A., Kim, H.J., and Kim, H.-J.
2008. Optimum conditions for production and purification of human papillomavirus type 16 L1 protein from
Protein Expr. Purif. 59
PubMed CrossRef Pastrana, D.V., Buck, C.B., Pang, Y.Y., Thompson, C.D., Castle, P.E., FitzGerald, P.C., Kruger Kjaer, S., Lowy, D.R., and Schiller, J.T.
2004. Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18.
PubMed CrossRef Pattenden, L.K., Middelberg, A.P., Niebert, M., and Lipin, D.I.
2005. Towards the preparative and large-scale precision manufacture of virus-like particles.
Trends Biotechnol. 23
PubMed CrossRef Schadlich, L., Senger, T., Kirschning, C.J., Muller, M., and Gissmann, L.
2009. Refining HPV 16 L1 purification from
: reducing endotoxin contaminations and their impact on immunogenicity.
PubMed CrossRef Stockmann, C., Scheidle, M., Dittrich, B., Merckelbach, A., Hehmann, G., Melmer, G., Klee, D., Buchs, J., Kang, H.A., and Gellissen, G.
2009. Process development in
, a re-assessment.
Microb. Cell Fact. 8
PubMed CrossRef Sun, J., Song, X., and Hu, S.
2008. Ginsenoside Rg1 and aluminum hydroxide synergistically promote immune responses to ovalbumin in BALB/c mice.
Clin. Vaccine Immunol. 15
PubMed CrossRef Thones, N., Herreiner, A., Schadlich, L., Piuko, K., and Muller, M.
2008. A direct comparison of human papillomavirus type 16 L1 particles reveals a lower immunogenicity of capsomeres than viruslike particles with respect to the induced antibody response.
J. Virol. 82
PubMed CrossRef Vicente, T., Roldao, A., Peixoto, C., Carrondo, M.J., and Alves, P.M.
2011. Large-scale production and purification of VLP-based vaccines.
J. Invertebr. Pathol. 107
PubMed CrossRef Walboomers, J.M., Jacobs, M.V., Manos, M.M., Bosch, F.X., Kummer, J.A., Shah, K.V., Snijders, P.J., Peto, J., Meijer, C.J., and Munoz, N.
1999. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide.
J. Pathol. 189
PubMed CrossRef Wheeler, C.M., Castellsague, X., Garland, S.M., Szarewski, A., Paavonen, J., Naud, P., Salmeron, J., Chow, S.N., Apter, D., Kitchener, H., and et al
. 2012. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.
Lancet Oncol. 13
PubMed CrossRef Woo, M.K., Hur, S.J., Park, S., and Kim, H.-J.
2007. Study of cell-mediated response in mice by HPV16 L1 virus-like particles expressed in
J. Microbiol. Biotechnol. 17
PubMed Zhang, T., Xu, Y., Qiao, L., Wang, Y., Wu, X., Fan, D., Peng, Q., and Xu, X.
2010. Trivalent Human Papillomavirus (HPV) VLP vaccine covering HPV type 58 can elicit high level of humoral immunity but also induce immune interference among component types.
PubMed CrossRef Copyright information
© The Microbiological Society of Korea and Springer-Verlag Berlin Heidelberg 2012